Kolexia
Gilson Pauline
Pharmacien
Institut de cancérologie de Lorraine
Vandoeuvre-lès-Nancy, France
64 Activités
188 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Adénocarcinome Tumeurs colorectales Tumeurs du poumon Tumeurs du pancréas Instabilité des microsatellites Tumeurs de l'ovaire Carcinome pulmonaire à petites cellules

Industries

B3TSI
4 collaboration(s)
Dernière en 2023
AstraZeneca
4 collaboration(s)
Dernière en 2022
MSD
1 collaboration(s)
Dernière en 2020
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Tumor-derived cell-free DNA and circulating tumor cells: partners or rivals in metastasis formation?
Clinical and experimental medicine   17 janvier 2024
GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles.
Cell reports. Medicine   22 décembre 2023
Integrated Molecular Characterization of HER2-Low Breast Cancer Using Next Generation Sequencing (NGS).
Biomedicines   28 novembre 2023
CRISPR/Cas9-mediated knock-in of BRCA1/2 mutations restores response to olaparib in pancreatic cancer cell lines.
Scientific reports   31 octobre 2023
Gene Mutations and Liquid Biopsy in ER-Positive Breast Cancers: A Small Step Forward, a Giant Leap for Personalization of Endocrine Therapy?
Cancers   27 octobre 2023
160P CICLADES-CE study: Genomic signatures detected in DNA from FFPE samples of patients with advanced or metastatic breast cancers treated with anti-aromatase and CDK4/6 inhibitors
Molecular Analysis for Precision Oncology Congress 2023 4-6 October 2023   01 octobre 2023
2331P Interest of next generation sequencing (NGS) for integrated molecular diagnosis of HER2-low breast cancer
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
Validation of the Idylla GeneFusion assay to detect fusions and MET exon-skipping in non-small cell lung cancers.
Scientific reports   09 août 2023
DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy.
Frontiers in oncology   08 décembre 2022
66P DDB2 influences epithelial-to-mesenchymal transition and sensitivity to chemotherapy in pancreatic ductal adenocarcinoma cells
Molecular Analysis for Precision Oncology Congress 2022 14-16 October 2022   01 octobre 2022